BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Geier A, Gartung C, Dietrich CG, Wasmuth HE, Reinartz P, Matern S. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol 2003; 9(12): 2681-2685 [PMID: 14669312 DOI: 10.3748/wjg.v9.i12.2681]
URL: https://www.wjgnet.com/1007-9327/full/v9/i12/2681.htm
Number Citing Articles
1
Albert J. Czaja. The Overlap Syndromes of Autoimmune HepatitisDigestive Diseases and Sciences 2012;  doi: 10.1007/s10620-012-2367-1
2
Michael Lin, S. Chris Pappas. Managing Gastrointestinal Complications of Diabetes2017; : 93 doi: 10.1007/978-3-319-48662-8_7
3
Albert J Czaja. Current and future treatments of autoimmune hepatitisExpert Review of Gastroenterology & Hepatology 2009; 3(3): 269 doi: 10.1586/egh.09.15
4
Albert J. Czaja. Diagnosis and Management of Autoimmune HepatitisClinics in Liver Disease 2015; 19(1): 57 doi: 10.1016/j.cld.2014.09.004
5
Yasuhiro Miyake. Autoimmune Liver Diseases2014; : 95 doi: 10.1007/978-4-431-54789-1_7
6
Ja Kyung Kim. Treatment of Autoimmune HepatitisThe Korean Journal of Gastroenterology 2023; 81(2): 72 doi: 10.4166/kjg.2023.011
7
John M. Vierling. Diagnosis and Treatment of Autoimmune HepatitisCurrent Gastroenterology Reports 2012; 14(1): 25 doi: 10.1007/s11894-011-0236-2
8
Albert J Czaja. Drug choices in autoimmune hepatitis: Part A – steroidsExpert Review of Gastroenterology & Hepatology 2012; 6(5): 603 doi: 10.1586/egh.12.40
9
Silja Steinmann, Ansgar W. Lohse. Treatment of autoimmune hepatitis: Budesonide does not solve our problemsHepatology 2023; 77(4): 1071 doi: 10.1097/HEP.0000000000000183
10
Ignasi Olivas, Marina Cobreros, María-Carlota Londoño, Álvaro Díaz-González. Budesonide in the first line treatment of patients with autoimmune hepatitisGastroenterología y Hepatología (English Edition) 2022; 45(7): 561 doi: 10.1016/j.gastre.2021.11.003
11
Thejus Jayakrishnan, Meera Babu, Steven Goodnow, Brent Hardman. Budesonide-Induced Hyperosmolar Hyperglycemic State Following Transjugular Intrahepatic Portosystemic ShuntAACE Clinical Case Reports 2020; 6(5): e265 doi: 10.4158/ACCR-2020-0216
12
A. J. Czaja. Review article: the management of autoimmune hepatitis beyond consensus guidelinesAlimentary Pharmacology & Therapeutics 2013; 38(4): 343 doi: 10.1111/apt.12381
13
Iliana Doycheva, Kymberly D. Watt, Aliya F. Gulamhusein. Autoimmune hepatitis: Current and future therapeutic optionsLiver International 2019; 39(6): 1002 doi: 10.1111/liv.14062
14
Saeed Mohammad. Budesonide as first-line therapy for non-cirrhotic autoimmune hepatitis in children: a decision analysisScandinavian Journal of Gastroenterology 2016; 51(6): 753 doi: 10.3109/00365521.2015.1130166
15
Albert J. Czaja. Liver Disorders2017; : 217 doi: 10.1007/978-3-319-30103-7_15
16
Raj A Shah, Kris V Kowdley. Current and potential treatments for primary biliary cholangitisThe Lancet Gastroenterology & Hepatology 2020; 5(3): 306 doi: 10.1016/S2468-1253(19)30343-7
17
AbdulrahmanA Aljumah, Badr Al Jarallah, Ali Albenmousa, Abdullah Al Khathlan, Adnan Al Zanbagi, Mohammed Al Quaiz, Bandar Al-Judaibi, Khalid Nabrawi, Waleed Al Hamoudi, Mohammed Alghamdi, Hind Fallatah. The Saudi association for the study of liver diseases and transplantation clinical practice guidelines for management of autoimmune hepatitisSaudi Journal of Gastroenterology 2018; 24(7): 1 doi: 10.4103/sjg.SJG_159_18
18
Albert J Czaja. Current and prospective pharmacotherapy for autoimmune hepatitisExpert Opinion on Pharmacotherapy 2014; 15(12): 1715 doi: 10.1517/14656566.2014.931938
19
Ignasi Olivas, Marina Cobreros, María-Carlota Londoño, Álvaro Díaz-González. Budesonide in the first line treatment of patients with autoimmune hepatitisGastroenterología y Hepatología 2022; 45(7): 561 doi: 10.1016/j.gastrohep.2021.11.012
20
A. D. YEOMAN, M. S. LONGHI, M. A. HENEGHAN. Review article: the modern management of autoimmune hepatitisAlimentary Pharmacology & Therapeutics 2010; 31(8): 771 doi: 10.1111/j.1365-2036.2010.04241.x
21
C. Corpechot, O. Chazouillères. Hépatites auto-immunes : actualités diagnostiques et thérapeutiquesLa Revue de Médecine Interne 2010; 31(9): 606 doi: 10.1016/j.revmed.2009.05.015
22
John M. Vierling. Autoimmune Hepatitis and Overlap Syndromes: Diagnosis and ManagementClinical Gastroenterology and Hepatology 2015; 13(12): 2088 doi: 10.1016/j.cgh.2015.08.012
23
Farhad Sahebjam, John M. Vierling. Autoimmune hepatitisFrontiers of Medicine 2015; 9(2): 187 doi: 10.1007/s11684-015-0386-y
24
Andrew S. deLemos. Diagnosis and Management of Autoimmune Hepatitis2020; : 81 doi: 10.1007/978-3-030-33628-8_5
25
Albert J Czaja. Clinical Features, Differential Diagnosis and Treatment of Autoimmune Hepatitis in the ElderlyDrugs & Aging 2008; 25(3): 219 doi: 10.2165/00002512-200825030-00005
26
Eve A. Roberts. Autoimmune hepatitis from the paediatric perspectiveLiver International 2011; 31(10): 1424 doi: 10.1111/j.1478-3231.2011.02603.x
27
V. Selvarajah, A. J. Montano‐Loza, A. J. Czaja. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugsAlimentary Pharmacology & Therapeutics 2012; 36(8): 691 doi: 10.1111/apt.12042
28
Teru Kumagi, Khalid Alswat, Gideon M. Hirschfield, Jenny Heathcote. New insights into autoimmune liver diseasesHepatology Research 2008; 38(8): 745 doi: 10.1111/j.1872-034X.2008.00366.x
29
Aldo J Montano Loza, Albert J Czaja. Current therapy for autoimmune hepatitisNature Clinical Practice Gastroenterology & Hepatology 2007; 4(4): 202 doi: 10.1038/ncpgasthep0768
30
Albert J Czaja, Yusuf Bayraktar. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatmentWorld Journal of Gastroenterology 2009; 15(19): 2314-2328 doi: 10.3748/wjg.15.2314
31
Albert J Czaja. Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future DirectionsGut and Liver 2016; 10(2): 177 doi: 10.5009/gnl15352
32
Andréanne N. Zizzo, Pamela L. Valentino, Prakesh S. Shah, Binita M. Kamath. Second‐line Agents in Pediatric Patients With Autoimmune HepatitisJournal of Pediatric Gastroenterology and Nutrition 2017; 65(1): 6 doi: 10.1097/MPG.0000000000001530
33
Cara L. Mack, David Adams, David N. Assis, Nanda Kerkar, Michael P. Manns, Marlyn J. Mayo, John M. Vierling, Mouaz Alsawas, Mohammad H. Murad, Albert J. Czaja. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver DiseasesHepatology 2020; 72(2): 671 doi: 10.1002/hep.31065
34
Natanie J. Anilovich. Oral budesonide is an effective alternative to prednisone for treatment of autoimmune hepatitisClinical Research In Practice: The Journal of Team Hippocrates 2021; 7(2) doi: 10.22237/crp/1622160960
35
Syed Rizvi, Samer Gawrieh. Autoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic ManagementDrugs & Aging 2018; 35(7): 589 doi: 10.1007/s40266-018-0556-0
36
Lydia A. Mercado, Fernando Gil-Lopez, Razvan M. Chirila, Denise M. Harnois. Autoimmune Hepatitis: A Diagnostic and Therapeutic OverviewDiagnostics 2024; 14(4): 382 doi: 10.3390/diagnostics14040382
37
T. O. Lankisch, C. P. Strassburg, M. P. Manns. Autoimmune Liver DiseaseFalk Symposium 2005; 142: 193 doi: 10.1007/1-4020-2914-4_18
38
Albert J. Czaja. Liver Disorders2017; : 307 doi: 10.1007/978-3-319-30103-7_18
39
Albert J. Czaja. Evolving paradigm of treatment for autoimmune hepatitisExpert Review of Clinical Immunology 2017; 13(8): 781 doi: 10.1080/1744666X.2017.1319764
40
Agnes Nuo Han, Beatrice Rae Han, Tao Zhang, Tycho Heimbach. Hepatic Impairment Physiologically Based Pharmacokinetic Model Development: Current ChallengesCurrent Pharmacology Reports 2021; 7(6): 213 doi: 10.1007/s40495-021-00266-5
41
Luigi Muratori, Paolo Muratori, Alessandro Granito, Giorgios Pappas, Fabio Cassani, Marco Lenzi. Current topics in autoimmune hepatitisDigestive and Liver Disease 2010; 42(11): 757 doi: 10.1016/j.dld.2010.05.019
42
Paul A. Schmeltzer. Diagnosis and Management of Autoimmune Hepatitis2020; : 93 doi: 10.1007/978-3-030-33628-8_6
43
Albert J. Czaja, Michael P. Manns. Advances in the Diagnosis, Pathogenesis, and Management of Autoimmune HepatitisGastroenterology 2010; 139(1): 58 doi: 10.1053/j.gastro.2010.04.053
44
Albert J. Czaja. Advances in the Current Treatment of Autoimmune HepatitisDigestive Diseases and Sciences 2012; 57(8): 1996 doi: 10.1007/s10620-012-2151-2
45
EASL Clinical Practice Guidelines: Autoimmune hepatitisJournal of Hepatology 2015; 63(4): 971 doi: 10.1016/j.jhep.2015.06.030
46
O. Chazouillères. Un cas d’hépatite auto-immuneGastroentérologie Clinique et Biologique 2009; 33(10-11): F36 doi: 10.1016/j.gcb.2009.07.015
47
Brian H Le, Ghauri Aggarwal, Carol Douglas, Michael Green, Amanda Nicoll, Sam Ahmedzai. Oxycodone/naloxone prolonged‐release tablets in patients with moderate‐to‐severe, chronic cancer pain: Challenges in the context of hepatic impairmentAsia-Pacific Journal of Clinical Oncology 2022; 18(1): 13 doi: 10.1111/ajco.13561
48
Nahum Méndez-Sánchez, Carlos E. Coronel-Castillo, Ana L. Ordoñez-Vázquez. Current Therapies for Cholestatic DiseasesBiomedicines 2023; 11(6): 1713 doi: 10.3390/biomedicines11061713
49
Charles Ronsin, Pierre Braud, Christine Kandel-Aznar, Amaury Dujardin, Clémence Petit, David Larmet, Claire Garandeau, Clément Deltombe, Alice Le Clech, Claire Leman, Gilles Blancho, Juliet Schurder, Grégoire Couvrat-Desvergnes, Simon Ville. Clinical Presentation, Pathological Spectrum, and Outcomes of Alcoholic Cirrhosis-Related Immunoglobulin A NephropathyKidney International Reports 2024;  doi: 10.1016/j.ekir.2024.02.1397
50
Albert J. Czaja, Herschel A. Carpenter. Autoimmune Hepatitis Overlap Syndromes and Liver PathologyGastroenterology Clinics of North America 2017; 46(2): 345 doi: 10.1016/j.gtc.2017.01.008